During the last budget period, the Cancer Center has undergone an expansive reorganization of its administrative, scientific and educational goals and initiatives. Guided by a comprehensive and inclusive strategic planning process that engaged all ofthe stakeholders ofthe cancer research enterprise, comprehensive directives were implemented that realigned scientific Programs for multidisciplinary collaboration, reorganized Shared Resources for optimal impact and penetration, launched a portfolio of educational and mentoring initiatives and created inter-institutional partnerships along the continuum of basic, translational and patient-oriented cancer research. One of the key strategic directives of the consultative process was the creation of a dedicated administrative infrastructure ideally suited to guide the anticipated expansion ofthe Cancer Center during the next CCSG budget period, coinciding with the opening of the new Wistar Research Tower This resulted in the creation of a new Cancer Center leadership team, the reorganization of consultative and advisory venues, the appointment of new advisory committees, and the creation of a new Cancer Center-dedicated External Advisory Board. As emerged from the strategic planning process, this newly reconfigured, integrated administrative infrastructure provided a lean and opportunity-driven decision-making process for the Cancer Center. This was instrumental to enable a broad range of successful initiatives during the last budget period, which positioned the Cancer Center on a steep ascending trajectory with respect to growth of NCI and cancer-related funding, increase in collaborative publications and seminal scientific discoveries in basic and translational cancer research. This positive trajectory will continue in the next budget period, as the newly reconfigured Cancer Center administrative infrastructure will lead the upcoming faculty and facility expansion, expand education and mentoring activities, including outreach to underrepresented minorities, and support multidisciplinary initiatives in basic and translational cancer research

Public Health Relevance

In past CCSG budget periods, the Wistar Institute and its NCI-designated Cancer Center shared entirely their administrative infrastructure and decision-making venues. This has now changed as part ofthe comprehensive reorganization ofthe Cancer Center, and a dedicated administrative and leadership team is now in place to advance the cancer research agenda in the upcoming facility and faculty expansion

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA010815-49
Application #
9438879
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2018-03-01
Budget End
2019-02-28
Support Year
49
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Wistar Institute
Department
Type
DUNS #
075524595
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Papasavvas, Emmanouil; Lada, Steven M; Joseph, Jocelin et al. (2018) Analytical ART interruption does not irreversibly change pre-interruption levels of cellular HIV. AIDS :
Duperret, Elizabeth K; Trautz, Aspen; Stoltz, Regina et al. (2018) Synthetic DNA-Encoded Monoclonal Antibody Delivery of Anti-CTLA-4 Antibodies Induces Tumor Shrinkage In Vivo. Cancer Res 78:6363-6370
Reyes-Uribe, Patricia; Adrianzen-Ruesta, Maria Paz; Deng, Zhong et al. (2018) Exploiting TERT dependency as a therapeutic strategy for NRAS-mutant melanoma. Oncogene 37:4058-4072
Kugel 3rd, Curtis H; Douglass, Stephen M; Webster, Marie R et al. (2018) Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations. Clin Cancer Res 24:5347-5356
Fukumoto, Takeshi; Park, Pyoung Hwa; Wu, Shuai et al. (2018) Repurposing Pan-HDAC Inhibitors for ARID1A-Mutated Ovarian Cancer. Cell Rep 22:3393-3400
Bhattacharjee, Souvik; Coppens, Isabelle; Mbengue, Alassane et al. (2018) Remodeling of the malaria parasite and host human red cell by vesicle amplification that induces artemisinin resistance. Blood 131:1234-1247
Lu, Yunqi; Hu, Zhongyi; Mangala, Lingegowda S et al. (2018) MYC Targeted Long Noncoding RNA DANCR Promotes Cancer in Part by Reducing p21 Levels. Cancer Res 78:64-74
Thangavel, Chellappagounder; Boopathi, Ettickan; Liu, Yi et al. (2018) Therapeutic Challenge with a CDK 4/6 Inhibitor Induces an RB-Dependent SMAC-Mediated Apoptotic Response in Non-Small Cell Lung Cancer. Clin Cancer Res 24:1402-1414
Duperret, Elizabeth K; Liu, Shujing; Paik, Megan et al. (2018) A Designer Cross-reactive DNA Immunotherapeutic Vaccine that Targets Multiple MAGE-A Family Members Simultaneously for Cancer Therapy. Clin Cancer Res 24:6015-6027
Duperret, Elizabeth K; Wise, Megan C; Trautz, Aspen et al. (2018) Synergy of Immune Checkpoint Blockade with a Novel Synthetic Consensus DNA Vaccine Targeting TERT. Mol Ther 26:435-445

Showing the most recent 10 out of 741 publications